BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist.

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.

Start Date31 Mar 2025

Sponsor / Collaborator

AstraZeneca PLC

NCT06862206

/ Not yet recruitingNot Applicable

A Multicentre, Single Arm, Non-interventional, Prospective Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

Start Date30 Mar 2025

Sponsor / Collaborator

AstraZeneca PLC

NCT06734884

/ Not yet recruitingPhase 2IIT

Efficacy and Safety of Anti-interleukin 5 Receptor Therapy (Benralizumab) in Patients With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)

Drug Reaction with eosinophilia and Systemic Symptoms (DRESS) is a rare and severe multiorgan drug reaction whose pathophysiological mechanisms underlying remain unclear, but may involve the role of several immune cells like eosinophils. iIndeed,the number of eosinophils is increased in blood and/or in organs tiisues in at least 50% of patients with DRESS. There is no specific treatment available. The standard of care is corticosteroids, but they may be inefficient or poorly tolerated. The aim of this research is to find out whether a specific treatment of the immunological response in DRESS syndrome would be useful in combination with corticosteroids to speed up the recovery from DRESS syndrome and therefore reduce the total length of your hospital stay when your illness is being managed. This a multicenter, international, prospective, interventional study, double-blinded, placebo-controlled, randomized, in two balanced parallel groups, one receiving the standard of care (topical or systemic corticosteroids, according to the severity of DRESS syndrome) and the other one corticsoteroids and a targeted therapy against eosinophils (benralizumab, already available in other eosinophilic diseases like asthma).

Start Date06 Jan 2025

Sponsor / Collaborator

AstraZeneca PLC

100 Clinical Results associated with Benralizumab

100 Translational Medicine associated with Benralizumab

100 Patents (Medical) associated with Benralizumab

860

Literatures (Medical) associated with Benralizumab

01 Dec 2025·Current Cardiology Reports

Eosinophilic Myocarditis: A Concise Review

Review

Author: Kahwash, Rami ; Trovato, Vincenzo ; Asada, Ashlee M

Abstract:

Purpose of Review:

Eosinophilic myocarditis (EM) is a rare and heterogeneous form of inflammatory heart disease that can present with a wide range of severity. Current literature is limited to case reports or small case series that outline the evaluation process, disease course, and the nonstandardized treatments trialed. This review aims to concisely summarize the current literature on EM including an update on maintenance therapy for refractory or recurrent disease.

Recent Findings:

In the last several years, several observational studies have reported the clinical benefit of mepolizumab and benralizumab in refractory EM.

Summary:

EM is a complex and heterogenous cause of inflammatory heart disease with a wide range of etiologies and presentations. Treatment of this disease has not been standardized as there are no large scale trials quantifying benefit of any specific therapy regimen. Targeted biologics show promise in observational studies; therefore, prospective studies are needed to quantify this benefit in EM.

01 May 2025·Respiratory Investigation

Successful treatment by switching from benralizumab to dupilumab in a patient with allergic bronchopulmonary mycosis caused by Schizophyllum commune

Article

Author: Sekiya, Muneyuki ; Motohashi, Takumi ; Sakamoto, Susumu ; Yaguchi, Takashi ; Tochigi, Naobumi ; Fukuda, Kohshi ; Kishi, Kazuma ; Kamei, Katsuhiko ; Nakamura, Yasuhiko ; Sasaki, Masakazu

A 79-year-old female patient with a history of bronchial asthma was diagnosed with allergic bronchopulmonary aspergillosis. Her symptoms temporarily improved with inhaled corticosteroid/long-acting β2-agonist therapy. However, 10 months after treatment, her asthma symptoms worsened. Sputum culture showed white cotton wool colonies, which were identified as Schizophyllum commune via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and gene sequencing. The patient tested positive for S. commune-specific IgG. Thus, she was diagnosed with Schizophyllum commune-induced allergic bronchopulmonary mycosis. The patient was initially treated with benralizumab. However, it was not effective. After switching to dupilumab, her symptoms and mucus plugs improved.

01 Mar 2025·Respirology Case Reports

Out of Breath, out of Options: Benralizumab as a Last Hope in ICU‐Treated Near‐Fatal Eosinophilic Asthma: A Case Series

Article

Author: Conemans, Lennart ; Simons, Sami ; Franssen, Frits ; Bischoff, Martijn ; Demir, Emel

ABSTRACT:

Asthma exacerbations remain life‐threatening events despite advancements in biologic therapies. This case series reports on four patients with near‐fatal eosinophilic asthma exacerbations who had been admitted to intensive care and were treated with benralizumab as a last resort after failing maximal standard therapies. All patients exhibited marked blood or airway eosinophilia and required intensive care ventilatory support. Following the administration of benralizumab, significant clinical improvements were observed. This series highlights the potential role of benralizumab in treating life‐threatening asthma exacerbations driven by eosinophilic airway inflammation and underlines the need for phenotyping and timely intervention in managing such patients with near‐fatal asthma while also stressing the need for continued adherence to asthma guidelines to prevent these extreme situations.

News (Medical) associated with Benralizumab

05 Feb 2025

·www.businesswire.com

Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board

BOULDER, Colo.--( BUSINESS WIRE )-- Enveda , a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, initially developed for atopic dermatitis, represents a breakthrough approach to respiratory inflammatory conditions. Enveda has assembled an advisory board comprising leading experts in asthma research and treatment to support this advancement. ENV-294: A Transformative Approach to Asthma ENV-294 is a clinical-stage small molecule designed to address the shared pathways underlying multiple inflammatory conditions via a first-in-class mechanism. ENV-294 entered Phase 1 studies in healthy subjects in Q4 2024 with the goal of treating atopic dermatitis. ENV-294 previously demonstrated strong efficacy in multiple preclinical studies concurrent with robust safety margins in IND-enabling studies. Enveda has since identified asthma as a high-impact follow-on indication for ENV-294 following promising preclinical and translational data in asthma models. This expansion underscores the company's ability to discover and leverage novel chemistry to provide transformative first-in-class therapies for patients. “ENV-294 has the potential to redefine asthma treatment by targeting key pathways involved in airway inflammation via a non-steroidal, orally delivered therapeutic,” said Viswa Colluru, Ph.D., CEO and Founder of Enveda . “We are thrilled to be working with a distinguished group of scientific and clinical leaders to guide our efforts in bringing this innovative therapy to patients. A major new asthma drug has not been approved in over a decade, highlighting the critical need for new treatments like ENV-294 to address unmet patient needs.” Formation of Enveda’s Asthma Advisory Board To accelerate the development of ENV-294 in asthma, Enveda has assembled an advisory board of renowned pulmonologists and asthma researchers. This panel will provide strategic insights and scientific expertise to advance the clinical development of ENV-294. The advisory board is chaired by Dr. Michael Wechsler , a globally recognized leader in asthma research and Director of the Cohen Family Asthma Institute at National Jewish Health. Esteemed advisory board members include: Dr. Michael Wechsler (Chair) – Professor of Medicine and Director of the Asthma Program at National Jewish Health. Dr. Wechsler is an expert in asthma pharmacogenomics and biologic therapies, with extensive experience in clinical trials for novel asthma treatments. He has played a pivotal role in the development of biologic therapeutics such as benralizumab, dupilumab, and tezepelumab. Dr. Geoffrey Chupp – Professor of Medicine at Yale University, specializing in severe asthma and eosinophilic lung diseases. Dr. Chupp is a leading researcher in identifying asthma biomarkers and has significantly contributed to understanding the pathophysiology of airway diseases. Dr. Praveen Akuthota – Professor of Clinical Medicine at the University of California, San Diego, a leading physician-scientist in eosinophilic pulmonary disease. Dr. Akuthota has contributed to landmark studies on eosinophilic asthma and is a principal investigator in NIH-funded precision medicine initiatives. Dr. Mario Castro – Chief of Pulmonary, Critical Care, and Sleep Medicine at the University of Kansas Medical Center. Dr. Castro is a highly respected authority on asthma pathogenesis and treatment, with over 300 peer-reviewed publications. He has led major clinical trials focused on innovative asthma therapies and precision medicine approaches. Dr. Jonathan Corren – Clinical consultant, educator, and research mentor at the University of California, Los Angeles, with expertise in allergy and immunology. Dr. Corren has decades of experience in clinical trial design and the development of targeted biologic therapies for asthma and allergic diseases. “The opportunity to work with Enveda on the development of ENV-294 is exciting,” said Dr. Wechsler . “Asthma remains a challenging disease with significant unmet needs, and ENV-294’s novel mechanism of action and oral route of administration has the potential to change the treatment paradigm for many patients.” Advancing Innovation in Respiratory Disease Enveda’s expansion into asthma aligns with its broader mission to harness the power of nature and machine learning to develop new medicines. The company remains committed to advancing innovative treatments for inflammatory diseases and improving patient outcomes. About Enveda Enveda is a biotechnology company that is learning from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms—the vast majority of which have never been explored by science—creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s pressing medical needs. For more information on Enveda, visit enveda.com .

Phase 1

15 Jan 2025

·www.pharmaceutical-technology.com

JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead

AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to bring in $80bn in revenue by 2030. CFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January. The company maintains a confident outlook for the new year, said Sarin, despite its share price decline in the latter half of 2024. During her presentation, Sarin focussed on the company’s performance during the first nine months of 2024, during which AstraZeneca increased total revenue by 19% against the same period in 2023 . Additionally, cash flow rose by almost $1bn over the prior year. The company’s growth was largely attributed to its expanded clinical pipeline, which includes late-stage trials that have increased in number from 77 in 2022 to 91 in 2024. This year promises to be a “catalyst-rich” year for AstraZeneca, according to Sarin, with 21 new molecular entities (NMEs) in late-stage development, seven of which are expected to yield Phase III readouts within the next year. Among these are gefurulimab, being trialled in myasthenia gravis (NCT05556096), and efzimfotase alfa, trialled in hypophosphatasia (NCT06079281), the progress of which Sarin attributed to accelerated recruitment rates. Sarin did, however, note negatively impacted revenues in China given ongoing investigations of AstraZeneca’s operations in the country by authorities. On 30 October 2024, AstraZeneca’s Chinese operations president Leon Wang stood down and was detained along with other current and former employees amidst accusations of insurance fraud, data breaches, and import of unlicenced medicines. Revenues for AstraZeneca in the US, in comparison, increased by 20% in the first nine months of 2024, comprising 43% of total revenue and are expected to account for half of the company’s revenues by 2030 according to Sarin. She identified respiratory and immunology as the company’s foremost sectors, growing by 39% in Q4 of 2024. Additionally, she said assets like Breztri (budesonide + formoterol fumarate + glycopyrrolate) and Fasenra (benralizumab) are positioned for indication expansion into severe asthma and chronic obstructive pulmonary disorder (COPD), respectively, during 2025. Sarin said AstraZeneca’s capital allocation priorities are unchanged for the coming year and that the company remains focussed on antibody-drug conjugates, bispecific antibodies, and cell therapies, in addition to continuing its foray into the metabolic and gene editing space. Like many other companies that rose to prominence during the Covid-19 pandemic, AstraZeneca has made concerted efforts to break into the obesity market, and has tried going through the deal rout with its potential acquisition agreement with SixPeaks Bio , announced in May 2024.

AcquisitionPhase 3

19 Dec 2024

·www.businesswire.com

Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases

PHILADELPHIA--( BUSINESS WIRE )--Tolerance Bio, Inc., a biopharmaceutical company pioneering innovative approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the formation of its Scientific Advisory Board (SAB) and the completion of its oversubscribed $20.2 million seed financing round. Tolerance Bio is developing an allogeneic, or “off the shelf,” induced pluripotent stem cell (iPSC)-based thymus cell therapy platform as well as pharmacological thymus therapies to address immune-mediated diseases. These diseases are caused by abnormalities in immune tolerance, including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies. The Company announced the completion of its seed financing round with the addition of Pacific 8 Ventures to the previously announced syndicate led by Columbus Venture Partners, with participation from Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners, and individual biotechnology investors. To support the Company’s research and development (R&D) initiatives, Tolerance Bio also announced the formation of its Scientific Advisory Board (SAB). “ The Tolerance Bio team is humbled by the exceptional advisors and investors supporting our mission to preserve, restore and manipulate the thymus to address immune diseases and potentially increase longevity,” said Francisco Leon, M.D., Ph.D., Co-Founder and Chief Executive Officer of Tolerance Bio. “ Each advisor is a leader in their respective fields, providing the Company with unbiased insights and guidance as we advance our programs in immunology, oncology, and beyond. We are incredibly excited by the opportunities lying ahead.” Tolerance Bio’s SAB is comprised of the following members: Dr. Holger Russ, Ph.D. , is the Scientific Co-Founder of Tolerance Bio and its SAB Chairman. Dr. Russ is a pioneer in stem-cell derived thymic and beta cell generation. He is an Associate Professor in the Department of Pharmacology and Therapeutics at the Diabetes Institute of the University of Florida. He is also an Honorary Senior Research Fellow at the Institute of Metabolism & Systems Research at the University of Birmingham in the UK. Dr Russ’s research focuses on the generation of functional human thymic and pancreatic islets from pluripotent stem cells. He has made significant contributions to the field of regenerative medicine and is a co-inventor on eight patents in this area. Dr. Megan Sykes, M.D., is the Michael J. Friedlander Professor of Medicine and Professor of Microbiology & Immunology and Surgical Sciences (in Surgery) at Columbia University. She is Director of the Columbia Center for Translational Immunology, Director of Research for the Transplant Initiative, and Director of Bone Marrow Transplantation Research at Columbia University Medical Center. Dr. Sykes has published more than 500 papers and book chapters during her research career, focusing on hematopoietic cell transplantation, organ allograft tolerance induction, xenotransplantation tolerance, and Type 1 diabetes. She has developed novel strategies for achieving GVL effects without GVHD following hematopoietic cell transplantation (HCT). One such approach provided safety and efficacy data in clinical trials of non-myeloablative haploidentical HCT that permitted the use of HCT for the intentional achievement of organ allograft tolerance in humans. Her work on xenogeneic thymic transplantation for tolerance induction has been extended into non-human primate and human studies. She has used mixed chimerism to reverse autoimmunity while replacing destroyed islets of Langerhans in Type 1 diabetes and developed novel “human immune system (HIS) mouse” models that allow personalized analysis of the pathogenesis of human immune disorders such as Type 1 diabetes. She has also used the HIS mouse model to understand human T cell repertoire development and assess the impact of stem cell-derived human thymic epithelial cells on human T cell development in a porcine thymus. Dr. Sykes is the Past President of the International Xenotransplantation Association, was President of the Federation of Clinical Immunology Societies (FOCiS) from 2022-2024, a recipient of the Medawar Prize, and a member of the National Academy of Medicine. Dr. Camillo Ricordi, M.D., FNAI, is a Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Chief of the Division of Cellular Transplantation, Department of Surgery, Director of the Cell Transplant Center and Director Emeritus of the Diabetes Research Institute (DRI). Since 1993, he has been the Medical Director of the NIH-funded cGMP Advanced Human Cell and Biologic Product Manufacturing Facility, supporting global research and clinical applications. Dr. Ricordi is renowned for inventing groundbreaking technology to isolate islet cells from the human pancreas, revolutionizing islet transplantation for diabetes treatment. He led the first successful clinical islet allotransplants using purified donor islets, reversing diabetes through intra-hepatic infusion. This transformational procedure is now standard practice in clinical islet transplantation worldwide. In 1993, he joined the University of Miami to lead the DRI and Cell Transplant Center. Among his achievements, Dr. Ricordi led the first successful implantation of a bioengineered endocrine pancreas for patients with severe Type 1 Diabetes and chaired the NIH Phase 3 trial on islet transplantation. Currently, he serves as Chairperson of the International Steering Committee and Principal Investigator for two stem cell-derived islet transplant trials. A founding president of key professional organizations, Dr. Ricordi has received numerous accolades, including the World Prize in Surgery, the American Diabetes Association’s Outstanding Scientific Achievement Award, the Leonardo Da Vinci Award, and induction into the National Academy of Inventors. His extensive contributions include over 1,170 publications, 58,000 citations, 28 patents, and the bestselling book The Healthspan Code . Dr. Jerome Ritz, M.D. ’s research focuses on immune reconstitution after hematopoietic stem cell transplantation, cellular therapies, and cancer immunotherapy. Dr. Ritz has co-authored more than 450 scientific publications in peer-reviewed journals and contributed to numerous presentations at leading scientific conferences. From 1996 until June 2024, Dr. Ritz was Executive Director of the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) at the Dana Farber Cancer Institute in Boston, Massachusetts. This GMP facility manufactures a variety of cellular products, including genetically modified hematopoietic stem cells, CAR T cells, NK cells, regulatory T cells, invariant NKT cells, and cancer vaccines for patients enrolled in early phase clinical trials. He is a Professor of Medicine at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, and continues to lead a research team at the Dana-Farber Cancer Institute. Dr. Manasi Jaiman, M.D., MPH , is the global, mission-driven Chief Medical Officer of Aardvark Therapeutics, and an expert on cell therapy clinical development. Dr. Jaiman advances breakthrough therapies through the integration of medicine and technology, drawing from 15 years of clinical development, device development, regulatory filings, direct patient care, and scientific research. She was the Chief Medical Officer of ViaCyte, a beta cell therapy company acquired by Vertex in 2022. Through her expertise in stem cell therapy disease and diabetes, she developed the world’s first-in-human protocol using gene-edited cells in a medical device for Type 1 diabetes and successfully executed the clinical trials. Dr. Jaiman also developed the first outpatient clinical trial to study a bi-hormonal artificial pancreas in adults and pediatrics at MassGeneral Hospital, then led clinical trials utilizing the bionic pancreas device, now used at Beta Bionics. Dr. Roland Kolbeck, Ph.D. , is co-owner and the Chief Scientific Officer of Spirovant and an expert on biologic therapeutics in immune diseases. Dr. Kolbeck is an accomplished biotech executive specializing in respiratory sciences and drug discovery. His career spans more than 20 years of research and executive leadership experience, including Vice President and Head of Respiratory, Inflammation, and Autoimmune research at MedImmune/AstraZeneca. At MedImmune, he led the development of FASENRA®, AstraZeneca’s first biological for the treatment of severe eosinophilic asthma, and contributed to the spinout of six pre/clinical-stage autoimmune assets. Previously, he held senior scientific roles at Peptimmune and Millennium Pharmaceuticals. Dr. Kolbeck also served as an Associate Professor in the Department of Pathology and Molecular Medicine at McMaster University from 2014-2022. He earned a PhD from the University of Regensburg and Max Planck Institute of Neurobiology, Munich. About Tolerance Bio, Inc. Tolerance Bio, Inc., is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases. The Company is based in Philadelphia, PA. For more information, visit www.tolerancebio.com or follow us on LinkedIn . About Pacific 8 Ventures Pacific 8 Ventures is a venture fund focusing at the nexus of new technology platforms and medicine. Pacific 8 Ventures typically backs transformative biotech and healthcare founders at the early stages. For more information, please visit: www.pac8.com

Phase 3Cell TherapyImmunotherapyExecutive Change

100 Deals associated with Benralizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09874	Benralizumab	R03DX10	DB12023

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Granulomatosis With Polyangiitis	Japan	AstraZeneca KK	27 Dec 2024
Churg-Strauss Syndrome	United States	AstraZeneca AB	17 Sep 2024
Severe asthma	United States	AstraZeneca AB	17 Sep 2024
Eosinophilic Asthma	European Union	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	Iceland	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	Liechtenstein	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	Norway	AstraZeneca AB	08 Jan 2018
Asthma	United States	AstraZeneca AB	14 Nov 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sinusitis	NDA/BLA	United States	AstraZeneca PLC	14 Mar 2022
Eosinophilic Enteropathy	Phase 3	United States	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Japan	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Brazil	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Italy	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Netherlands	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Poland	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Spain	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Ukraine	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Vietnam	AstraZeneca PLC	18 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05552508 (BURAN, CTgov)	Phase 4	Asthma \| Eosinophilic Asthma	45	Benralizumab	svezylspaf(azptivbzuo) = qpnhyrcuum zjfodfsrua (vmyyvvqxrk, 0.4199) View more	-	25 Mar 2025
NCT04157348 (MANDARA, CTgov)	Phase 3	Churg-Strauss Syndrome	140	Benralizumab (Benralizumab 30 mg)	dlahdsrfbp = gcjyudeqti libwbovxba (spismonuft, jurtyetgsl - oysxyxvifd) View more	-	14 Jan 2025
				Mepolizumab (Mepolizumab 300 mg)	dlahdsrfbp = xswlwwczku libwbovxba (spismonuft, ugpfepxgnu - vmpqrhhyds) View more
NCT04159519 (CTgov)	Phase 4	Asthma \| Eosinophilic Asthma	170	salbutamol+Symbicort+benralizumab (Treatment Reduction)	cdxieuntub = tafcogkxvj bvvbmocoos (rdqlzpyyzt, fgyatgywug - ytdnnsgxxm) View more	-	09 Jan 2025
				salbutamol+Symbicort+benralizumab (Reference)	oimuljyflr(kfwafatiqo) = ssyjuqkcdn czewrhnpww (tvzgqwmwgd, 0.0677) View more
NCT05384938 (FAST, CTgov)	Phase 4	Asthma	139	Benralizumab	tjrufwbuqb = cilcrtpkip qwsoclejrn (ywlobonwow, nwzsvdmukn - qxwxevaore) View more	-	11 Dec 2024
NCT04612790 (FJORD, CTgov)	Phase 3	Pemphigoid, Bullous	67	Benralizumab (DB Period: Benralizumab)	ytzeimblhe = bvsoxmvhtq qpunekwuca (ygjpiccief, xdwkgjiwrd - cowujnfkik) View more	-	29 Nov 2024
				placebo+benralizumab (DB Period: Placebo)	ytzeimblhe = hamnhwnpnr qpunekwuca (ygjpiccief, kjjrkiqcku - bjhkcconto) View more
NCT04098718 (Pubmed) Manual	Phase 2	Pulmonary Disease, Chronic Obstructive \| Eosinophilic Asthma	158	benralizumab	vrglyiuhst(pelnmhlqdj) = The 28-day total VAS mean difference was 49 mm (95% CI 14-84; p=0·0065), favouring the pooled-BENRA group. rvzlfcjctj (yyiwuzpzsf ) View more	Positive	27 Nov 2024
				benralizumab
NCT04157348 (MANDARA, FDA_CDER) Manual	Phase 3	Churg-Strauss Syndrome	140	FASENRA	fktbminygt(mhaulmwbzh) = ujcnmtkmuq ehydbmvdhn (iunaqerwjk ) View more	Non-inferior	17 Sep 2024
				Mepolizumab	fktbminygt(mhaulmwbzh) = fwtarfjslw ehydbmvdhn (iunaqerwjk ) View more
NCT01928771 \| NCT01914757 (FDA_CDER) Manual	Phase 3	Asthma	-	FASENRA (SIROCCO)	ocxfxxikep(eldmtdhxpd) = oigtcsendp vtcrkaqqku (yauisjdzmg )	Positive	17 Sep 2024
				Placebo (SIROCCO)	ocxfxxikep(eldmtdhxpd) = edjrokohlb vtcrkaqqku (yauisjdzmg )
ATS2024	Not Applicable	Hypereosinophilic Syndrome \| Adenocarcinoma of Lung	-	Osimertinib	vbzangcrfy(ydbsyrnulg) = Hypereosinophilic syndrome (HES) is a rare condition defined by more than 1500 eosinophil cells/µL in peripheral blood. It can be primary to clonal hematopoiesis, secondary to cytokines related eosinophilic production or idiopathic. If left untreated it can lead to multisystem end organ damage xoxxzyxcns (pcitnxutqv )	-	19 May 2024
				Benralizumab
NCT03186209 (CTgov)	Phase 3	Asthma	695	Placebo	pvnrnuajgm(qujgoplvjq) = fqmnihrwlg convengdmc (mcsmhlexid, inexhraxkb - ylvclogyrr) View more	-	24 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis